TY - JOUR T1 - Controlling COVID-19 via test-trace-quarantine JF - medRxiv DO - 10.1101/2020.07.15.20154765 SP - 2020.07.15.20154765 AU - Cliff C. Kerr AU - Dina Mistry AU - Robyn M. Stuart AU - Katherine Rosenfeld AU - Gregory R. Hart AU - Rafael C. Núñez AU - Prashanth Selvaraj AU - Jamie A. Cohen AU - Romesh G. Abeysuriya AU - Lauren George AU - Brittany Hagedorn AU - Michał Jastrzębski AU - Meaghan Fagalde AU - Jeffrey Duchin AU - Michael Famulare AU - Daniel J. Klein Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154765.abstract N2 - COVID-19 containment efforts in the United States so far have largely focused on physical distancing, including school and workplace closures. However, these interventions have come at an enormous societal and economic cost. Here, we use an agent-based model, calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region, to investigate the feasibility of alternative control strategies, focusing on “test-trace-quarantine”: a combination of (a) routine testing of primarily symptomatic individuals, (b) tracing and testing their known contacts, and (c) placing their contacts in quarantine. We assess the requirements for implementing this strategy, including its robustness to low compliance, delays, and other factors such as variability in overall transmission rates. We find that for the Seattle setting, if mask compliance remains high and schools remain closed, realistic levels of testing and tracing are sufficient to maintain epidemic control under a return to full workplace and community mobility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by Bill and Melinda Gates through the Global Good Fund. Institutional support, including high-performance computing resources and library access, was provided by the Burnet Institute and the University of Sydney School of Physics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Covasim model code is fully open source and available via GitHub. Most data are available from the King County Data Dashboard; data not publicly released are available upon request with permission from Public Health Seattle & King County. Analysis scripts are available from the authors upon request. https://github.com/institutefordiseasemodeling/covasim ER -